Updated on 22 June 2016
As explored in an abstract presented at the 2016 American Society of Clinical Oncology (ASCO) conference, the launch of Roche's recently approved PD-1 immune checkpoint inhibitor Tecentriq (atezolizumab) will usher in a dramatic change in the treatment paradigm of metastatic bladder cancer, according to an analyst with research and consulting firm GlobalData.
The company's most recent bladder cancer report states that the disease's setting has been largely stagnant for almost 20 years, which largely explains why Tecentriq has generated a considerable level of interest.
In fact, on the heels of its approval as a second-line therapy following failure on platinum-based chemotherapy, there is already buzz about its potential expansion into the first-line setting.
GlobalData believes that the trial results presented at ASCO 2016 showed Tecentriq to be worthy of its praise.
Of the 119 patients who were treated with Tecentriq once every three weeks in the drug's Phase II, single-arm IMvigor 210 trial, overall response rate was reported to be 24% in all patients, with 7% being complete responses at a median follow-up of 14.4 months.